CANTINI, LUCA
 Distribuzione geografica
Continente #
NA - Nord America 1.654
EU - Europa 410
AS - Asia 181
AF - Africa 62
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 2
SA - Sud America 1
Totale 2.313
Nazione #
US - Stati Uniti d'America 1.654
IT - Italia 122
IE - Irlanda 95
CN - Cina 84
SE - Svezia 84
SG - Singapore 73
CI - Costa d'Avorio 44
GB - Regno Unito 34
UA - Ucraina 21
DE - Germania 20
MA - Marocco 18
IN - India 16
BE - Belgio 11
FR - Francia 8
DK - Danimarca 4
JP - Giappone 4
KR - Corea 4
EU - Europa 3
RO - Romania 3
AU - Australia 2
FI - Finlandia 2
NL - Olanda 2
AT - Austria 1
BG - Bulgaria 1
PL - Polonia 1
RU - Federazione Russa 1
VE - Venezuela 1
Totale 2.313
Città #
Chandler 292
Des Moines 268
Ashburn 109
Fairfield 108
Boardman 93
Dublin 90
New York 87
Ann Arbor 53
Wilmington 49
Woodbridge 46
Seattle 45
Abidjan 44
Cambridge 36
Houston 36
Jacksonville 35
Lawrence 34
Princeton 34
Turin 31
Singapore 29
San Mateo 27
San Diego 24
Pune 16
Washington 16
Beijing 14
Los Angeles 12
Brussels 11
Dallas 11
London 11
Ancona 10
Shenzhen 7
Guangzhou 6
Redmond 6
Falls Church 5
Shanghai 5
Tolentino 5
Wuhan 5
Arnold 4
Civitanova Marche 3
Fermignano 3
Kilburn 3
Prescot 3
Qingdao 3
Wuxi 3
Bellante 2
Caserta 2
Castelraimondo 2
Centro 2
Fabriano 2
Jiaxing 2
Kagoya 2
Macerata 2
Milan 2
Norwalk 2
Parma 2
Recanati 2
Seoul 2
Slobozia 2
Zhengzhou 2
Acerra 1
Acton 1
Amandola 1
Amsterdam 1
Bolton 1
Brandenburg 1
Brisbane 1
Chiswick 1
Clifton 1
Dangan 1
Dortmund 1
Falconara Marittima 1
Falkenstein 1
Foshan 1
Genzano di Roma 1
Helsinki 1
Hounslow 1
Islington 1
Jesi 1
Limido Comasco 1
Long Beach 1
Mantova 1
Mestre 1
New Bedfont 1
Osimo 1
Phoenix 1
Redwood City 1
Saint Petersburg 1
San Costanzo 1
Sioux Falls 1
Southwark 1
Stockholm 1
Tower Hamlets 1
Vienna 1
Warsaw 1
Yiwu 1
Totale 1.798
Nome #
Are liver nested stromal epithelial tumors always low aggressive? 115
Impact of polypharmacy for chronic ailments in colon cancer patients: A review focused on drug repurposing. 103
Optimal management of resected gastric cancer 100
Acute Peripheral Motor Neuropathy Induced by Oxaliplatin-Correlated Hypokalaemia 96
Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: a systematic review and meta-analysis 91
Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients 91
Role of DCE-MR imaging of the breast in predicting breast cancer subtypes: where are we going? 87
High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients 87
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis 84
Scientia Potentia Est: How the Italian World of Oncology Changes in the COVID-19 Pandemic 84
BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma 75
Long‑responders to anti‑HER2 therapies: A case report and review of the literature 71
The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab 71
An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer 69
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 66
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 66
Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer 65
Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC 64
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study 63
Seroprevalence of SARS-CoV-2-Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy 63
Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer 59
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy 57
Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis 56
Prognostic Impact of Ki-67 Change in Locally Advanced and Early Breast Cancer after Neoadjuvant Chemotherapy: A Single Institution Experience 56
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer 52
Re: Comments on 'High-intensity statins are associated with improved clinical activity of programmed cell death protein 1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients' 50
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study 49
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy 45
Corrigendum to 'The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer': [ESMO Open Volume 6, Issue 2, April 2021, 100078] 40
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario 40
Cancer patient perspective in the arena of COVID-19 pandemic 36
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status 35
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study 34
Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study 31
Pachychoroid spectrum disease and choriocapillary flow analysis in patients with Cushing disease: an optical coherence tomography angiography study 30
Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients 27
Rising incidence of late stage breast cancer after COVID-19 outbreak. Real-world data from the Italian COVID-DELAY study 21
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study 19
Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry 17
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 14
Pachychoroid spectrum disease and choriocapillary flow analysis in patients with Cushing disease: an optical coherence tomography angiography study 6
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research 5
Totale 2.390
Categoria #
all - tutte 14.994
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.994


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202057 0 1 2 1 5 1 6 4 5 13 6 13
2020/2021360 7 13 60 57 33 6 8 31 25 24 53 43
2021/2022296 3 28 5 6 18 36 13 18 51 17 38 63
2022/2023939 58 97 43 72 47 316 0 46 151 9 80 20
2023/2024463 72 12 31 35 52 154 3 9 0 18 7 70
2024/2025234 155 79 0 0 0 0 0 0 0 0 0 0
Totale 2.390